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Background: Three subpopulations of monocytes can be distinguished in human blood: classical (CD14++CD16−),
intermediate (CD14++CD16+), and nonclassical (CD14+CD16++). CD16 expressing monocytes are expanded in
patients with sarcoidosis and in various other inflammatory diseases. In sarcoidosis, it is unclear whether either
intermediate, nonclassical or both CD16 expressing monocytes are responsible for this increase. Data relating to
the monocyte subpopulations is receiving increasing attention, but the expression of TNF receptors on these
subpopulations has not been studied thus far. The aim of this study was to determine frequencies of monocyte
subpopulations and their expression of TNFR1 and TNFR2 in both sarcoidosis patients and healthy controls.
Methods: Peripheral blood cells of sarcoidosis patients and healthy controls were stained for the markers HLA-DR,
CD14, CD16, CD120a and CD120b. Cells were measured on a FACSCalibur and analyzed with FlowJo. We used
Student’s t-test and a parametric One-way ANOVA for statistical analysis.
Results: Sarcoidosis patients had a significant higher frequency of intermediate monocytes than healthy controls.
Significant differences in TNF receptor expression were found between the monocyte subpopulations, both in
sarcoidosis patients as well as in healthy controls: intermediates expressed more TNFR1 than classicals and
nonclassicals and nonclassicals expressed more TNFR2 than intermediates, whereas intermediates showed higher
expression than classicals.
Conclusions: In both sarcoidosis patients and healthy controls intermediate monocytes show the highest
expression level of TNFR1 among monocyte subpopulations and nonclassical monocytes show the highest
expression level of TNFR2. These findings, as wells as the higher frequency of intermediate monocytes in sarcoidosis
patients, provide evidence for the existence of two functionally-distinct CD16 expressing monocyte subpopulations.
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Monocytes originate from myeloid progenitors in the
bone marrow, circulate in the blood for up to three days,
and then enter peripheral tissues where they differentiate
into macrophages or dendritic cells [1].
Human monocytes can be divided into three subpopu-
lations: classical, intermediate, and nonclassical. This
subdivision is based on the expression levels of the* Correspondence: g.rijkers@antoniusziekenhuis.nl
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reproduction in any medium, provided the orlipopolysaccharide (LPS) coreceptor CD14 and the Fcγ
receptor III CD16. Classical monocytes, the major popu-
lation of monocytes, are CD14++CD16−. The minor
population of CD16 expressing monocytes are further
subdivided in intermediate monocytes (CD14++CD16+)
and nonclassical monocytes (CD14+CD16++) [2]. Re-
cently, monocyte subpopulations have been extensively
investigated. In addition to CD14 and CD16, also other
markers, such as HLA-DR, CCR2 and CCR5, can distin-
guish the three human monocyte subpopulations [3,4].
An imbalance in the relative proportion of CD16
expressing monocytes has been found in a variety of im-
mune mediated diseases such as rheumatoid arthritis,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Sarcoidosis patients show a higher frequency of
intermediate monocytes than healthy controls. Percentage of
intermediates within the monocyte population of patients with
sarcoidosis (n = 38) and healthy controls (n = 13). Data are presented
as box plots, where the boxes represent the 25th to 75th percentiles,
the lines within the boxes represent the median, and the lines
outside the boxes represent the 10th and 90th percentiles.
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(reviewed by Ziegler-Heitbrock [5]). An increase in the
relative number of CD16 expressing monocytes was
found in newly diagnosed sarcoidosis patients, suggest-
ing an activated state of the monocytes. This activated
state might be an indicator for disease activity [6,7].
These investigations have not discriminated between the
two CD16 expressing monocyte subpopulations. Re-
cently, it has been shown in patients with rheumatoid
arthritis [8] and severe asthma [9] that intermediate
monocytes are responsible for the increase in CD16
expressing monocytes. So far, this has not been investi-
gated in patients with sarcoidosis.
Sarcoidosis is a systemic, granulomatous disease of un-
known origin that primarily affects the lungs. It is a di-
sease of all races and ethnic groups with varying
incidence throughout the world [10-12]. The highest in-
cidence of sarcoidosis in Europe has been reported from
Sweden: 24 cases per 100,000 [13]. In The Netherlands,
the incidence of sarcoidosis is estimated to be 20 cases
per 100,000 [14]. In the United States, the incidence rate
in black people is 36 cases per 100,000 compared to 11
cases per 100,000 in white people [15]. The most im-
portant feature of sarcoidosis is the formation of non-
caseating granulomas [10-12].
In the human lung, tumor necrosis factor (TNF) is
mainly produced by alveolar macrophages and thought
to play a major role in the development of the granu-
lomatous inflammation. The release of TNF is increased
in the lung of patients with pulmonary sarcoidosis
[16,17]. Therefore TNF is an attractive target for im-
munotherapy in sarcoidosis.
TNF exerts its function by binding to and signaling via
two different receptors. TNFR1 (CD120a) is constitutively,
but in low levels, expressed on nearly all nucleated cell
types. TNFR2 (CD120b) is inducible and expressed by
cells of myeloid lineage, peripheral T cells and alveolar
lymphocytes and macrophages [18-23]. TNFR1 activates
the caspase family, which induce cell death. TNFR2 sig-
nalling leads to NF-ĸB transcription and can induce proli-
feration, differentiation, cytokine production and even
apoptosis. When TNFR1 and TNFR2 are co-expressed on
the same cells, intracellular cross-talk between the recep-
tors may occur [24]. Both TNF receptors can be enzymati-
cally cleaved from the cell surface and form soluble TNF
receptors. Soluble TNF receptors can neutralize TNF and
clear it from the circulation and act as a TNF antagonist,
but can also prolong its bioactivity by binding TNF and
thus stabilize the trimeric structure [22]. Membrane-
bound TNF binds more strongly to TNFR2 than soluble
TNF does. It may be that TNFR2 only becomes fully
activated with membrane-bound TNF [21].
There are a few reports of TNFR1 and TNFR2 ex-
pression on peripheral blood cells. Approximately 25%of the peripheral blood lymphocytes in healthy subjects
is CD4+TNFR2+. Interestingly, in sarcoidosis the per-
centage of CD4+TNFR2+ cells is increased, especially in
patients in remission or with stable disease (respectively
35% and 33%), which may indicate a role in down regu-
lation of a cell-mediated immune response [23]. FoxP3+
T reg cells expressed the highest levels of TNFR2 among
subsets of human peripheral blood CD4+ T cells and
were able to shed large amounts of sTNFR2, suggesting
an important role for T reg cells in suppressing TNF
[25]. It is attractive to speculate about a similar role for
one of the subpopulations of human monocytes. How-
ever, the expression of TNFR1 and TNFR2 on monocyte
subpopulations has not been studied thus far.
The aim of the present study was to determine fre-
quencies of the three monocyte subpopulations in pe-
ripheral blood of patients with sarcoidosis compared to
healthy controls and the relative expression of TNFR1
and TNFR2 on these subpopulations.
Methods
Patients and healthy controls
Thirty-eight patients (11 female, 27 male; median age 48
years, range 22–70 years) with proven sarcoidosis were
included in the present study. For this study, all
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of severity of the disease and independent of use of
medication. Thirteen healthy volunteers (4 female, 9
male; median age 50 years, range 27–58 years) were used
as controls. Peripheral blood was collected in sodium
heparin tubes. The study was approved by the medical
ethical evaluation committee of the St Antonius Hospital
in Nieuwegein, The Netherlands.
Antibodies and flow cytometry
Anti-HLA-DR FITC and anti-CD16 PE were obtained
from BD Biosciences (San Diego, CA, USA). Anti-CD14
PerCP-eFluor710 was from eBioscience (San Diego, CA,
USA). Anti-CD120a APC (TNFR1) and anti-CD120b
APC (TNFR2) were from R&D Systems (Minneapolis,
MN, USA). After staining, flow cytometry data were
acquired on a FACSCalibur (BD Biosciences) and analyzed
using FlowJo software (Tree Star, Ashland, OR, USA).
Monocytes were gated based on FSC x SSC and SSC x
HLA-DR+ expression. Subsequently, monocytes wereFigure 2 Differential expression of HLA-DR, CD14, CD16 on monocyte
Median fluorescence intensity (MFI) of HLA-DR (A,B), CD14 (C) and CD16 (D
nonclassical (CD14+CD16++) monocytes in sarcoidosis patients (n = 38) and
data in panel A are regrouped in panel B to allow better comparison betw
mean± SEM. All three markers were significantly different between the thre
controls, nonclassical monocytes showed significant different levels of HLA
levels of CD14 expression. Comparison of three groups of data (subpopula
and comparison of two groups of data (patients versus controls) was perfosubdivided in three populations based on CD14 and
CD16 expression pattern. We used fluorescence minus
one (FMO) staining as control for the TNF receptor
staining by substracting the MFI of the FMO control of
the MFI of the TNF receptor.
Statistical analysis
Data are expressed as mean± SEM. Comparison of two
groups of data (patients versus controls) was performed
by a two-tailed Student’s t-test and comparison of three
groups of data (subpopulations of monocytes) was per-
formed by a parametric One-way ANOVA, both by using
GraphPad Prism version 5.0 for Windows (GraphPad
Software, San Diego, CA, USA). Differences were consid-
ered statistically significant at P values of 0.05 or less.
Results and discussion
Monocytes subpopulations
The frequency of classical, intermediate, and nonclassical
monocyte subpopulations was analyzed in 38 sarcoidosissubpopulations in sarcoidosis patients and healthy controls.
) on classical (CD14++CD16−), intermediate (CD14++CD16+) and
in healthy controls (n = 13). Please note that, for sake of clarity, the
een the monocyte subpopulations. Values are expressed as
e monocyte subpopulations. Between sarcoidosis patients and healthy
-DR expression and classical monocytes showed significant different
tions of monocytes) was performed by a parametric One-way ANOVA
rmed by a two-tailed Student’s t-test.
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CD14 and CD16 expression pattern. In this study, classical
monocytes accounted for 60–90% of SSC x HLA-DR+
gated monocytes, intermediate monocytes for about 2–5%
and nonclassical monocytes for 5–25%, both in sarcoidosis
patients as well as in healthy controls. Others (reviewed
by Ziegler-Heitbrock [5]) have found increased or
decreased relative numbers of CD16 expressing mono-
cytes in a variety of inflammatory and/or infectious dis-
eases in man. In most of these studies nonclassical and
intermediate monocytes were grouped together as one
subpopulation. Rossol et al. reported that increased fre-
quencies of CD16 expressing monocytes in rheumatoid
arthritis were due to an increase in intermediates [8].
Moniuszko et al. reported similar findings for severe
asthma [9].We also found a higher frequency of inter-
mediate monocytes in sarcoidosis patients (3.08%±0.25%)
than in healthy controls (1.98%±0.22%; P=0.017; Figure 1),
while nonclassical monocytes were not increased (data
not shown). It should be stressed that CD16 expressing
monocytes should be considered as two different
populations.
All three monocyte subpopulations differed signifi-
cantly in HLA-DR expression, both in sarcoidosis
patients as well as in healthy controls. Intermediates
showed the highest expression of HLA-DR, followed by
nonclassicals (P < 0.0001; Figure 2A). This differential
expression of HLA-DR on monocyte subpopulations
previously has been described for patients with rheuma-
toid arthritis [8] and for healthy controls [3].
We found significant differences in HLA-DR and CD14
expression between patients with sarcoidosis and healthyFigure 3 Differential expression of TNFR1 and TNFR2 on monocyte su
fluorescence intensity (MFI) of TNFR1 (A) and TNFR2 (B) on classical (CD14++
monocytes in sarcoidosis patients (TNFR1 n=18, TNFR2 n=38) and in health
fluorescence minus one (FMO) control. Values are expressed as mean±SEM.
subpopulations. All monocytes expressed TNFR1, but intermediates had a hig
also expressed TNFR2, but nonclassicals had a higher expression of TNFR2 th
Comparison of the three subpopulations of monocytes was performed by acontrols. Nonclassical monocytes of sarcoidosis patients
expressed a higher level of HLA-DR than nonclassicals of
controls (P=0.026; Figure 2B). Classical monocytes of sar-
coidosis patients expressed a lower level of CD14 than
classicals of healthy controls (P=0.030; Figure 2C). Inter-
mediate monocytes of sarcoidosis patients tended to have
a higher level of HLA-DR and a lower level of CD14 than
intermediates of healthy controls (Figures 2B and 2C).
Nonclassical and intermediate monocytes of sarcoidosis
patients tended to have a higher level of CD16 than non-
classicals and intermediates of controls (Figure 2D).TNF receptors
TNF is a major cytokine regulating the activity of mono-
cytes and therefore we have extended the phenotypic
characterization of monocyte subpopulations for expres-
sion of TNF receptors. Although no differences were
found between patients and controls, analysis of TNFR1
and TNFR2 revealed differential expression on the mono-
cyte subpopulations, both in sarcoidosis patients as well as
in healthy controls. All monocytes expressed TNFR1, but
intermediates showed a higher expression of TNFR1 than
classicals and nonclassicals (P< 0.05; Figure 3A). All
monocytes also expressed TNFR2, but the three subpopu-
lations showed major differences in TNFR2 expression
(P< 0.0001; Figure 3B). Nonclassical monocytes expressed
the highest levels of TNFR2. Intermediates expressed less
TNFR2 than nonclassicals, but more than classicals. Al-
though classical monocytes expressed the lowest levels of
TNFR2, values were still largely positive compared to a
fluorescence minus one (FMO) control.bpopulations in sarcoidosis patients and healthy controls. Median
CD16−), intermediate (CD14++CD16+) and nonclassical (CD14+CD16++)
y controls (TNFR1 n=5, TNFR2 n= 13) minus the MFI of the
Both markers were significantly different between the three monocyte
her expression of TNFR1 than classicals and nonclassicals. All monocytes
an intermediates and a much higher expression than classicals.
parametric One-way ANOVA.
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Subpopulations of monocytes not only express different
levels of CD14, CD16 and HLA-DR, but also different
levels of TNFR1 and TNFR2. This finding is new and
emphasizes the diversity and potential different func-
tions of the three monocyte subpopulations. Frequencies
of intermediate monocytes are increased in sarcoidosis
patients, suggesting an activated state of the monocytes
in this disease. This finding may be of especial relevance
because intermediate monocytes express the highest
level of HLA-DR among the monocyte subpopulations.
This activated state might be a novel indicator for dis-
ease activity. Intermediate monocytes also express the
highest level of TNFR1 among the monocyte subpopula-
tions, while nonclassical monocytes, the other CD16
expressing monocyte subpopulation, express the highest
level of TNFR2. This data supports the evidence of
two functionally-distinct CD16 expressing monocyte
subpopulations.
HLA-DR may be a valuable marker to monitor the dis-
ease course of sarcoidosis patients. Intermediate and
nonclassical monocytes plus their TNF receptor expres-
sion pattern might be relevant to monitor for sarcoidosis
patients who are going to be treated with anti-TNF
(Remicade), as well as for other patients on anti-TNF
therapy, such as those suffering from rheumatoid ar-
thritis, psoriasis or Crohn’s disease. Prospective monitoring
of these patients should demonstrate whether particular
monocyte subpopulations display differential sensitivity to
this form of treatment and whether this correlates with
the clinical response.
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